Home LiteratureArticle Details
PMID: 19871529 Published · ppublish English Journal Article

STUDIES ON THE COMPLEMENT FIXATION ANTIGENS OF INFLUENZA VIRUSES TYPES A AND B.

The Journal of experimental medicine ·Vol. 83 ·No. 4 ·1946-03-31 ·Pages 259-79

Wiener M, Henle W, Henle G

Abstract

Two types of specific particles can be obtained from allantoic fluid preparations of influenza A and B virus. The larger particle which possesses all the attributes of the virus and which shows a sedimentation constant of about 600 S was compared with the smaller component (30 S) by complement fixation technic. The 30 S component can be differentiated from the 600 S particle by the patterns of the optimal antigen-antibody relationships and by cross-absorption of the sera with the two particles. Some of the 30 S-type antigen can be demonstrated in higher concentrations of the 600 S particles by the use of sera containing only anti-30 S; i.e., sera carefully absorbed with 600 S component. Also, upon sonic vibration of the 600 S particle, serologically active material was released which behaved in every respect like the 30 S antigen. The response of human beings to these antigens was found to vary. Antibodies to the 30 S component developed in the majority of subjects exposed to active virus either under epidemic or experimental conditions, but only rarely following vaccination with three different vaccines. In selecting sera without 30 S antibodies a fairly close correlation between the antibody titers obtained by inhibition of hemagglutination and complement fixation with the 600 S component was obtained. The presence of 30 S antibodies prevented such a correlation. The reaction with the 30 S antigen may be of value in the diagnosis and study of the epidemiology of influenza.

Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Wiener M
Department of Pediatrics, School of Medicine, University of Pennsylvania, the Children's Hospital of Philadelphia, and the Department of Bacteriology, Woman's Medical College of Pennsylvania, Philadelphia.
Henle W
Henle G
References (10)
10 references, click to expand
  1. Etiological and Serological Studies in Epidemic Influenza.
    Am J Public Health Nations Health. 1937 Nov;27(11):1141-60 PMID: 18014734
  2. THE TOXICITY OF INFLUENZA VIRUSES.
    Science. 1945 Oct 19;102(2651):398-400 PMID: 17755277
  3. STUDIES ON EPIDEMIC INFLUENZA VIRUS : THE NATURE AND PROPERTIES OF THE COMPLEMENT-FIXING ANTIGEN.
    J Exp Med. 1940 Aug 31;72(3):233-46 PMID: 19871020
  4. STUDIES ON THE NATURE OF THE VIRUS OF INFLUENZA : II. THE SIZE OF THE INFECTIOUS UNIT IN INFLUENZA A.
    J Exp Med. 1943 Mar 1;77(3):265-76 PMID: 19871281
  5. THE PREPARATION AND PROPERTIES OF INFLUENZA VIRUS VACCINES CONCENTRATED AND PURIFIED BY DIFFERENTIAL CENTRIFUGATION.
    J Exp Med. 1945 Feb 1;81(2):193-218 PMID: 19871452
  6. A SEDIMENTABLE COMPONENT OF ALLANTOIC FLUID AND ITS RELATIONSHIP TO INFLUENZA VIRUSES.
    J Exp Med. 1944 Aug 1;80(2):83-100 PMID: 19871405
  7. THE SIZE OF INFLUENZA VIRUS.
    J Exp Med. 1944 Mar 1;79(3):267-83 PMID: 19871369
  8. STUDIES ON INFLUENZA VIRUS : THE COMPLEMENT-FIXING ANTIGEN OF INFLUENZA A AND SWINE INFLUENZA VIRUSES.
    J Exp Med. 1941 Apr 30;73(5):581-99 PMID: 19871098
  9. CENTRIFUGATION AND ULTRAFILTRATION STUDIES ON ALLANTOIC FLUID PREPARATIONS OF INFLUENZA VIRUS.
    J Exp Med. 1944 Mar 1;79(3):301-17 PMID: 19871372
  10. NEUROLOGICAL SIGNS IN MICE FOLLOWING INTRACEREBRAL INOCULATION OF INFLUENZA VIRUSES.
    Science. 1944 Nov 3;100(2601):410-1 PMID: 17799459
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
1946-03-31
Pages
259-79
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2135605
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com